Nelson Christopher B, Birmingham Maureen, Costa Alejandro, Daviaud Joelle, Perea William, Kieny Marie-Paule, Tarantola Daniel
Department of Immunizations, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
Am J Public Health. 2007 Apr;97 Suppl 1(Suppl 1):S15-22. doi: 10.2105/AJPH.2005.075085. Epub 2007 Apr 5.
With the emergence of epidemic Neisseria meningitidis W135 meningitis in Burkina Faso during early 2002, the public health community was faced with the challenge of providing access to an appropriate and affordable vaccine in time for the upcoming 2003 epidemic season. Recognizing the implications of the emergent threat, the World Health Organization developed a strategy, established a public-private partnership to provide the needed vaccine, and then ensured that a stockpile was available for future use. The trivalent N meningitidis ACW135 polysaccharide vaccine that resulted is now one of the primary tools for epidemic response in African meningitis belt countries. It will remain so for the foreseeable future and until appropriate and affordable conjugate vaccines become part of national immunization programs in the region.
2002年初布基纳法索出现流行性脑膜炎奈瑟菌W135脑膜炎疫情，公共卫生界面临一项挑战，即要及时提供一种适宜且价格合理的疫苗，以应对即将到来的2003年流行季节。认识到这一突发威胁的影响后，世界卫生组织制定了一项战略，建立了公私伙伴关系以提供所需疫苗，随后确保储备有疫苗供未来使用。由此产生的三价A、C、W135群脑膜炎奈瑟菌多糖疫苗，现已成为非洲脑膜炎带国家应对疫情的主要工具之一。在可预见的未来，直至适宜且价格合理的结合疫苗成为该地区国家免疫规划的一部分之前，它都将保持这一地位。
